ResMed Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference
ResMed (NYSE: RMD, ASX: RMD) has announced that Mick Farrell, chairman and CEO, and Dr. Carlos Nunez, chief medical officer, will present at the 43rd Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
ResMed (NYSE: RMD, ASX: RMD) has announced that Mick Farrell, chairman and CEO, and Dr. Carlos Nunez, chief medical officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Monday, January 13, 2025, at approximately 3:00 p.m. (Pacific Standard Time) in San Francisco, CA.
The company will provide an audio-only webcast of the presentation, which can be accessed through the investor relations section of ResMed's website. A replay of the webcast will be available for 30 days following the live presentation.
Details
News Market Reaction – RMD
The recorded move for RMD in the trading session of this news was +0.56%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Dr. Carlos Nunez, chief medical officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, beginning at approximately 3:00 p.m. (Pacific Standard Time) in San Francisco, CA.
More information about this event, including access to the live, audio-only webcast, may be accessed by visiting https://investor.resmed.com. The audio-only webcast replay will be available approximately 24 hours after the live webcast ends and will be accessible for the following thirty (30) days.
About ResMed
At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit ResMed.com and follow @ResMed.
| For investors | For media |
| +1 858.836.5000 | +1 619.510.1281 |
| investorrelations@resmed.com | news@resmed.com |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.